TB-500 vs Thymosin Alpha-1

Side-by-side comparison of TB-500, Thymosin Alpha-1 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute TB-500 Thymosin Beta-4 Synthetic Analogue Recovery Thymosin Alpha-1 Thymosin Alpha-1 (Tα1) Longevity
Basics
Molecular type Thymic Peptide AnalogueThymic Peptide
Amino acids 4328
Molecular weight 4,921 Da3,108.4 Da
Half-life Long-acting (days)~2 hours
Route(s) Subcutaneous, IntramuscularSubcutaneous
Mechanism & Research
Primary mechanism TB-500's primary mechanism involves binding to G-actin (monomeric actin) through its conserved LKKTETQ sequence. By sequestering actin, it regulates cytoskeletal dynamics in ways that promote cell migration — a critical … Thymosin Alpha-1 stimulates T-cell differentiation and maturation, particularly enhancing T-helper cell (Th1) responses. This drives improved cell-mediated immunity — the arm of the immune system responsible for clearing…
Research status Research Compound Research Compound
Evidence summary TB-500 research spans cardiac regeneration, wound healing, hair follicle regeneration, and musculoskeletal repair. Most data is preclinical. Phase 1/2 trials with native Thymosin Beta-4 for cardiac indications have been … Thymosin Alpha-1 has extensive human clinical data from its regulatory approval in Asia and Europe for viral hepatitis and cancer adjunct therapy. Longevity applications build on this established safety and immune-modula…
Protocol & Dosing
Typical dose 5–10 mg per injection1.6 mg per injection (standard clinical dose)
Frequency 2x per week (loading), then weekly2x per week for 6–12 weeks
Duration 4–8 weeks6–12 weeks
Timing No specific timing requirementAny time of day
Safety
Common side effects
  • Injection site reaction
  • Mild fatigue (transient)
  • Headache
  • Lethargy in first days
  • Injection site redness
  • Mild flu-like symptoms (first injection)
  • Fatigue (transient)
Contraindications
  • Active cancer (angiogenic activity)
  • Pregnancy
  • Platelet disorders or anticoagulant use
  • Active autoimmune disease (immune stimulation risk)
  • Post-organ transplant (immunosuppression may be reversed)
  • Known allergy to thymic peptides
Anti-doping Prohibited (WADA S2) Not Prohibited
Deeper reading
Related peptides BPC-157, GHK-Cu, Thymosin Alpha-1 Epithalon, TB-500, LL-37
Full profile Read full TB-500 profile → Read full Thymosin Alpha-1 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.